GLOBAL
Ecron Acunova, a clinical research organization with offices across Europe, in India and the US, has strengthened its Eastern European presence further by opening a new office in Moscow, Russia in October 2009. Mrs Galyna Andriyko has been named as General Manager. She will lead the development of the Russian office operations.
“Russia has substantial unexplored capabilities. With its 141 million population and well recognized experience in clinical trials, Russia allows high recruitment rates, low drop-out rates and high quality data, to be obtained by dedicated medical professionals. With Mrs Andriyko’s expertise, we look forward to strengthening clinical trials in this region,” said Dr. Antal K. Hajos, Managing Director & CEO, Ecron Acunova, Europe said
Mrs Andriyko has successfully set up operations in Ukraine. The clinical team will be headed by Dr. Vlad Linievych, a physician, who has over 13 years of experience in industry. Ecron Acunova has been active in Russia for several years via collaborations and has 23 years of clinical expertise. Across Europe alone, Ecron Acunova covers 14 countries.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.